Artiva Biotherapeutics (NASDAQ:ARTV) Posts Quarterly Earnings Results, Misses Expectations By $0.24 EPS

Artiva Biotherapeutics (NASDAQ:ARTV) announced its earnings results on Tuesday. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.24), Zacks reports.

Artiva Biotherapeutics Trading Down 10.2 %

ARTV opened at $10.51 on Friday. The business has a 50-day moving average of $12.60. Artiva Biotherapeutics has a 12 month low of $9.68 and a 12 month high of $17.31.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ARTV shares. Jefferies Financial Group started coverage on Artiva Biotherapeutics in a research note on Tuesday, August 13th. They set a “buy” rating and a $21.00 price target on the stock. TD Cowen assumed coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They set a “buy” rating for the company. Needham & Company LLC reissued a “buy” rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Wednesday. Cantor Fitzgerald started coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued an “overweight” rating and a $23.00 price target for the company. Finally, Wedbush reissued an “outperform” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research note on Friday, August 30th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Artiva Biotherapeutics presently has an average rating of “Buy” and an average price target of $21.25.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.